Nothing Special   »   [go: up one dir, main page]

ATE430572T1 - Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie - Google Patents

Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie

Info

Publication number
ATE430572T1
ATE430572T1 AT03780370T AT03780370T ATE430572T1 AT E430572 T1 ATE430572 T1 AT E430572T1 AT 03780370 T AT03780370 T AT 03780370T AT 03780370 T AT03780370 T AT 03780370T AT E430572 T1 ATE430572 T1 AT E430572T1
Authority
AT
Austria
Prior art keywords
methoxyadenosine
treatment
pain
spongosin
hyperalgesia
Prior art date
Application number
AT03780370T
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Application granted granted Critical
Publication of ATE430572T1 publication Critical patent/ATE430572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03780370T 2002-12-09 2003-12-09 Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie ATE430572T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228723.3A GB0228723D0 (en) 2002-12-09 2002-12-09 Treatment of pain
PCT/GB2003/005379 WO2004052377A1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia

Publications (1)

Publication Number Publication Date
ATE430572T1 true ATE430572T1 (de) 2009-05-15

Family

ID=9949371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03780370T ATE430572T1 (de) 2002-12-09 2003-12-09 Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie

Country Status (19)

Country Link
US (2) US8252766B2 (de)
EP (1) EP1581235B1 (de)
JP (2) JP4836454B2 (de)
KR (1) KR101122495B1 (de)
CN (2) CN100471503C (de)
AT (1) ATE430572T1 (de)
AU (1) AU2003288451B2 (de)
CA (1) CA2507918A1 (de)
CY (1) CY1109229T1 (de)
DE (1) DE60327557D1 (de)
DK (1) DK1581235T3 (de)
ES (1) ES2326532T3 (de)
GB (2) GB0228723D0 (de)
HK (1) HK1086186A1 (de)
NO (1) NO20053042L (de)
NZ (1) NZ540353A (de)
PT (1) PT1581235E (de)
SI (1) SI1581235T1 (de)
WO (1) WO2004052377A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
KR20070004792A (ko) * 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
ATE500263T1 (de) 2006-06-27 2011-03-15 Cbt Dev Ltd Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
EP2081932A2 (de) 2006-06-27 2009-07-29 BIOVITRUM AB (publ) 2-o´-methyladenosinderivate und ihre verwendung als agonisten oder antagonisten eines adenosinrezeptors
AU2007263728A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
US8221791B1 (en) 2008-12-10 2012-07-17 University Of Central Florida Research Foundation, Inc. Silica-based antibacterial and antifungal nanoformulation
CN102470129A (zh) * 2009-07-09 2012-05-23 Cbt发展有限公司 作为药物使用的组合制剂
US20130123208A1 (en) * 2010-05-12 2013-05-16 The Regents of the University of Colorado, a body corporation Method of treating multiple sclerosis with adenosine receptor agonists
EP2631345B1 (de) * 2012-02-27 2019-09-04 Electrolux Home Products Corporation N.V. Waschwanneneinheit und Waschmaschine
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
EP3411032B1 (de) * 2016-02-04 2020-09-30 The Johns Hopkins University Rapadocine, inhibitoren des äquilibrierungsnukleosidtransporters 1 und verwendungen davon

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4861498A (de) 1971-12-01 1973-08-28
BE792155A (fr) 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
DE2359536C2 (de) 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5549594B2 (de) 1972-12-08 1980-12-12
JPS5461194A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en) 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
US5104859A (en) * 1985-09-24 1992-04-14 Solimedco Aktiebolag Continuous administration of adenosine to reduce pulmonary vascular resistance
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
WO1994023723A1 (en) 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
SE9401499D0 (sv) 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
JPH09512823A (ja) 1994-05-10 1997-12-22 サンド・リミテッド アデノシン誘導体
US5596094A (en) 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
EP0983768A1 (de) 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Arzneimittel zur vorbeugung bzw. zur behandlung von leberleiden
US6110902A (en) 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CA2296485A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EP1044004A1 (de) 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosin rezeptor agonisten in kombination mit typ iv phosphodiesterase inhibitoren
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
WO2004056181A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery (2)
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
KR20070004792A (ko) 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
US8407664B2 (en) 2005-12-30 2013-03-26 Sap Ag Software model business objects

Also Published As

Publication number Publication date
NO20053042L (no) 2005-06-21
GB0328548D0 (en) 2004-01-14
US20070010475A1 (en) 2007-01-11
CA2507918A1 (en) 2004-06-24
AU2003288451B2 (en) 2009-06-04
PT1581235E (pt) 2009-07-07
NZ540353A (en) 2006-11-30
JP4836454B2 (ja) 2011-12-14
DE60327557D1 (de) 2009-06-18
EP1581235A1 (de) 2005-10-05
JP2006514638A (ja) 2006-05-11
HK1086186A1 (en) 2006-09-15
WO2004052377A1 (en) 2004-06-24
KR20050089815A (ko) 2005-09-08
CN101264097B (zh) 2011-10-05
US8252766B2 (en) 2012-08-28
CN1723026A (zh) 2006-01-18
EP1581235B1 (de) 2009-05-06
DK1581235T3 (da) 2009-08-31
AU2003288451A1 (en) 2004-06-30
CY1109229T1 (el) 2013-09-04
KR101122495B1 (ko) 2012-03-15
JP2011132229A (ja) 2011-07-07
GB0228723D0 (en) 2003-01-15
GB2396108B (en) 2005-08-03
GB2396108A (en) 2004-06-16
CN101264097A (zh) 2008-09-17
ES2326532T3 (es) 2009-10-14
US20110184065A1 (en) 2011-07-28
SI1581235T1 (sl) 2009-10-31
CN100471503C (zh) 2009-03-25

Similar Documents

Publication Publication Date Title
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
ATE524125T1 (de) Platte und schrauben zur behandlung von knochenfrakturen
HK1087629A1 (en) Compounds for the treatment of pain
WO2006052718A3 (en) Farnesyltransferase inhibitors for treating sepsis
EA200401365A1 (ru) Способы лечения илеуса
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
MY138732A (en) Conjugated complement cascade inhibitors
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
ATE443044T1 (de) Tace inhibitoren
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE602004012759D1 (de) Behandlung von fibrosen
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1581235

Country of ref document: EP